Solara Active Pharma Sciences has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration for its Puducherry manufacturing facility. The regulatory development marks a significant milestone for the pharmaceutical company's operations at this location.

FDA Inspection Timeline and Outcome

The US FDA conducted an unannounced inspection of the Puducherry facility from February 2 to February 6, 2026. The inspection has been concluded with a Voluntary Action Indicated (VAI) status, with the agency issuing the EIR on April 24, 2026, and marking the inspection as "Closed".

Management Commentary

Commenting on the inspection outcome, Sandeep Rao, MD & CEO, stated that the company successfully completed the FDA inspection at the Puducherry facility. At the end of the inspection, four Form FDA 483 inspectional observations were issued by the investigator, which were procedural in nature. The company submitted its formal response to FDA within the stipulated timeline.

"The inspection outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy," Rao added.

Facility Specifications

The Puducherry site serves as an Ibuprofen manufacturing facility equipped with world-class infrastructure to cater to Ibuprofen and its derivatives requirements for domestic and international markets. The facility has been inspected by various regulatory authorities including US FDA, EDQM, MHRA, and HPRA.

Regulatory Significance

The VAI status represents a favorable outcome for pharmaceutical manufacturing facilities undergoing FDA inspection. This classification demonstrates that the Puducherry facility maintains appropriate manufacturing practices and quality standards as required by US regulatory authorities. The successful closure of the unannounced inspection exhibits the company's dedication to achieving quality excellence consistently across all manufacturing sites.

Solara Active Pharma Sciences Limited has issued a second and final call notice to eligible partly paid rights equity shareholders, marking a crucial step in converting these shares to fully paid status. The company dispatched the notice on April 06, 2026, in electronic mode to shareholders with registered email addresses, while physical copies were sent on April 07, 2026, to those without registered email addresses.

Call Payment Details

The second and final call requires shareholders to pay ₹112.50 per partly paid equity share, structured as follows:

The payment period spans 15 days, providing shareholders with a specific window to complete their obligations:

Payment Methods Available

Shareholders can utilize three distinct payment modes to fulfill their call money obligations:

• Online ASBA: Through Self-Certified Syndicate Banks (SCSBs) websites
• Physical ASBA: By submitting applications to designated SCSB branches
• 3-in-1 Online Accounts: Using linked trading-demat-bank accounts offered by brokers

The company emphasizes that cash payments will not be accepted, and partial payments will be treated as non-payment, potentially leading to share forfeiture.

Rights Issue Background

The current call relates to the company's rights issue executed under a Letter of Offer dated May 09, 2024. Key details of the original rights issue include:

Trading Suspension and Conversion Process

Trading of the ₹7 partly paid equity shares (ISIN: IN9624Z01022) has been suspended on stock exchanges effective April 02, 2026, due to the second and final call. Upon successful payment, the company's Board or authorized committee may convert partly paid shares to fully paid shares in tranches at their discretion.

The conversion process from ₹7 partly paid shares to ₹10 fully paid shares under ISIN INE624Z01016 is estimated to complete within two to three weeks after the Board's conversion decision. However, payments for partly paid shares in a particular demat account will be accepted only once during the payment period.

Consequences of Non-Payment

Shareholders failing to pay the second and final call money face significant consequences. The company reserves the right to deduct outstanding call amounts from future dividends and may forfeit partly paid shares, including amounts already paid, in accordance with the Companies Act, 2013, and the company's Articles of Association.

For queries and clarifications, shareholders can contact the Registrar and Share Transfer Agent, Cameo Corporate Services Limited, at +91 044 40020700 during business hours from Monday to Friday, 9 AM to 5 PM.